Fibroblast Growth Factor 19 Induced Changes in Non-malignant Cholangiocytes

Jiaqi Yang1, David Sontag1, Sam Kung2 and Gerald Y. Minuk1,3*

1Section of Hepatology, Department of Medicine, Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; 2Department of Immunology, Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; 3Department of Pharmacology and Therapeutics, Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Received: 9 March 2021 | Revised: 21 April 2021 | Accepted: 10 May 2021 | Published: 4 June 2021

Abstract

Background and Aims: Fibroblast growth factor (FGF19) has been implicated in the pathogenesis of murine hepatocellular carcinoma. Whether it plays a role in the development or course of human cholangiocarcinoma remains to be determined. The aim of this study was to determine whether prolonged exposure to FGF19 results in the transformation of non-malignant human cholangiocytes into cells with malignant features. Methods: Human SV-40 transfected non-malignant H69 cholangiocytes were cultured with FGF19 (0–50 ng/mL) for 6 weeks, followed by 6 weeks with medium alone. Cell proliferation, invasion, stem cell surface markers, oncofetoprotein expression, state of differentiation, epithelial-mesenchymal transition (EMT) and IL-6 expression. However, each of these effects returned to baseline or control values during the 6-week FGF19 free follow-up period. The remaining cell properties remained unaltered. Conclusions: Six weeks of FGF19 exposure did not result in the acquisition of permanent malignant features in non-malignant, human cholangiocytes.

Citation of this article: Yang J, Sontag D, Kung S, Minuk GY. Fibroblast growth factor 19 induced changes in non-malignant cholangiocytes. J Clin Transl Hepatol 2021;9(6):909–916. doi: 10.14218/JCTH.2021.00087.

Keywords: Fibroblast growth factor 19; Cholangiocytes; Cholangiocarcinoma; Farnesoid x receptor; Obeticholic acid.

Introduction

Fibroblast growth factor (FGF)-fibroblast growth factor receptor (FGFR) signaling plays an important role in cell proliferation, differentiation, migration, morphogenesis and angiogenesis.1 To date, 22 structurally-related FGFs and 5 cognate receptors (FGFR 1–5) have been identified.2–4 FGF19 is one of only three FGFs that function as an endocrine factor or hormone. Bile acid activation of farnesoid x receptors (FXRs) in the enterocytes of the ileum enhances its expression. FGF19 is then transported to the liver via the portal vein, where it inhibits CYP7A1 expression and thereby bile acid synthesis creating a negative feedback loop.5 As a result of these properties, bile acids, such as obeticholic acid (OCA), are presently being employed or tested as treatments for cholesstatic liver diseases and non-alcoholic steatohepatitis in humans where toxic bile acids are thought to be involved in the pathogenesis of these disorders.

In addition to its role in inhibiting bile acid synthesis, FGF19 has also been linked to regulating the development and progression of cancers, including hepatocellular carcinoma (HCC), by activating the Wingless/Wnt signaling pathway and resulting in nuclear accumulation of β-catenin and epithelial-mesenchymal transition (EMT).6–8 Indeed, ectopic FGF19 expression in transgenic mice results in increased hepatocyte proliferation, oncofetoprotein expression and hepatic tumor formation.6 In addition, FGF19 and its cognate receptor FGFR4 are overexpressed in premalignant cirrhotic livers and human HCC.7 Finally, FGF19 interference prevents tumor formation in FGF19 transgenic mice treated with the carcinogenic agent diethylnitrosamine.7

Relative to hepatocytes, there are a paucity of studies documenting the effects of FGF19 or its inducers on another important cell population of the liver: cholangiocytes. In one of the few papers published to date, OCA exposure exacerbated bile duct injury in a rat model of cholestasis.9 In another, FGF19 was found to selectively activate BiP and CHOP in a dose-dependent manner and regulate P-eIF2α and MAPK protein expression with a bimodal response.10 Perhaps of more concern are results of a study in which FGF4 tumor expression was increased in approximately 50–60% of 200 patients with intrahepatic ICC, perihilar (PCC) or distal (DCC) cholangiocarcinoma (CAA) and served as an independent prognostic factor in ICC and PCC patients.11

In

Copyright: © 2021 The Author(s). This article has been published under the terms of Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. This article has been published in Journal of Clinical and Translational Hepatology at https://doi.org/10.14218/JCTH.2021.00087 and can also be viewed on the Journal’s website at http://www.jcthnet.com/.
the same report, the authors described increased proliferation, invasion, and EMT in various malignant CCA cell lines exposed to FGF19.

Given previous data describing FGF19-FGF4R promotion of HCC, the association between FGF19/FGF4R and established CCA, the documented effects of FGF19 on malignant, CCA cell lines and anticipated long-term use of FXR agonists in patients with chronic liver disorders, we endeavored to determine whether prolonged exposure of nonmalignant human cholangiocytes to FGF19 results in their permanent acquisition of malignant features.

Methods

Cell lines

The human non-malignant, transformed bile duct epithelial cell line H69 was obtained from Dr. Gianfranco Alpini at Texas A&M University (College Station, TX, USA). H69 cells were cultured in Dulbecco’s modified Eagle’s medium (low glucose; Gibco, Invitrogen, Waltham, MA, USA), 25% Ham’s F12 (Invitrogen), 10% fetal bovine serum (FBS) (Invitrogen), 4 mmol/L L-glutamine (Invitrogen), 180 μmol/L adenine (Sigma-Aldrich, St. Louis, MO, USA), 5 mg/L insulin (Invitrogen), 5 mg/L transferrin (Sigma-Aldrich), 2 mmol/L triiodothyronine (Sigma-Aldrich), 1.1 μmol/L hydrocortisone (Sigma-Aldrich), 5.5 μmol/L epinephrine (Sigma-Aldrich), 1.64 μmol/L epidermal growth factor (EGF) (Invitrogen), 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen). Cells were incubated at 37°C in a humidified atmosphere of 5% CO2 and 95% air.

Cell cultures

H69 cells were seeded in 6-well plates, cultured in complete H69 medium and exposed to different concentrations of recombinant FGF19 (0, 0.5 ng/mL, 5 ng/mL, and 50 ng/mL) (Invitrogen) for 6 weeks, followed by FGF19-free H69 medium for an additional 6 weeks. Cell features were analyzed after 1, 2, 3, 4, 5, 6, 8 and 12 weeks of culture, unless otherwise stated.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

RNA of cells was extracted using a TRizol™ Plus RNA Purification Kit (Invitrogen) and quantified by a NanoDrop™ 2000 spectrophotometers (Thermo Fisher Scientific, Waltham, MA, USA). The RNA was reverse transcribed into complementary DNA (cDNA) following the instructions of iScriptTM cDNA synthesis kit Reverse Transcription Kit (Bio-Rad, Hercules, CA, USA). Real-time PCR was performed with SYBR® Green PCR Master Mix (Applied Biosystems Inc., Foster City, CA, USA). Data were analyzed by QuantStudioTM Real-time PCR Software (Applied Biosystems Inc.). The relative expression of genes was calculated by means of relative quantification (2−ΔΔCt method), with β-actin as an internal control.

Methods

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

RNA of cells was extracted using a TRizol™ Plus RNA Purification Kit (Invitrogen) and quantified by a NanoDrop™ 2000 spectrophotometers (Thermo Fisher Scientific, Waltham, MA, USA). The RNA was reverse transcribed into complementary DNA (cDNA) following the instructions of iScriptTM cDNA synthesis kit Reverse Transcription Kit (Bio-Rad, Hercules, CA, USA). Real-time PCR was performed with SYBR® Green PCR Master Mix (Invitrogen). The specific primers employed are listed in Table 1 and were designed with the respective sequences from GenBank by Oligo 7 software. PCR amplification was initially held at 54°C for 1 reagent (Takara Bio USA, New York City, NY, USA) at 37°C for 3 h. Absorbance of each well, compared against a blank control, was measured using a microplate reader (SynergyTM 4; BioTek Instruments, Winooski, VT, USA) at 540 nm.

Invasion assay

H69 cultured cells exposed to the different concentrations of FGF19 for the different time periods were seeded at a density of 2,000 cells per well in 96-well plates. After 24 h of plating, cells were incubated with a premixed WST-1 reagent (Takara Bio USA, New York City, NY, USA) at 37°C for 3 h. Absorbance of each well, compared against a blank control, was measured using a microplate reader (SynergyTM 4; BioTek Instruments, Winooski, VT, USA) at 540 nm.

Stem cell surface markers (SCSMs) and differentiation

H69 cultured cells exposed to the different concentrations of FGF19 for different time periods (1, 6, 8 and 12 weeks) were cultured in Dulbecco’s modified Eagle’s medium for an additional 6 weeks. Cell features were analyzed after 1, 2, 3, 4, 5, 6, 8 and 12 weeks of culture, unless otherwise stated.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

RNA of cells was extracted using a TRizol™ Plus RNA Purification Kit (Invitrogen) and quantified by a NanoDrop™ 2000 spectrophotometers (Thermo Fisher Scientific, Waltham, MA, USA). The RNA was reverse transcribed into complementary DNA (cDNA) following the instructions of iScriptTM cDNA synthesis kit Reverse Transcription Kit (Bio-Rad, Hercules, CA, USA). Real-time PCR was performed with SYBR® Green PCR Master Mix (Applied Biosystems Inc., Foster City, CA, USA). Data were analyzed by QuantStudioTM Real-time PCR Software (Applied Biosystems Inc.). The relative expression of genes was calculated by means of relative quantification (2−ΔΔCt method), with β-actin as an internal control.

Table 1. Primers of real-time polymerase chain reaction

| Gene   | Primers, 5’-3’ |
|--------|----------------|
| K167   | Forward GCTGTCGGGACCCCTACAGA |
|       | Reverse GCTGTCACTGCGGGTGTG |
| IL6    | Forward ACTCACCTCTCAGAAGCAATG |
|       | Reverse CCATTTTGAAAGGGTGTTT |
| CEA    | Forward TCTGTCGATTTGATGGGAAC |
|       | Reverse CACTGCTGATTTGATGGGAAC |
| CA125  | Forward AGGCCACCTCATCTATTACACA |
|       | Reverse TGTGTCGATTTGATGGGAAC |
| CYP7A1 | Forward GAGAAAGCCAAACGGTGTAAC |
|       | Reverse GGATTGCAACAAATTGCAGA |
| VIM    | Forward AGTCACTGAGTACCGGAC |
|       | Reverse CATTCTGCGATCTCGGCTT |
| MUC1   | Forward TGCCCGCAGAAAGAATCAG |
|       | Reverse TGGGGTACTCGCTCATAGGAT |
| CDH2   | Forward TGGGGTACTCGCTCATAGGAT |
|       | Reverse ATGCACATCCTCGGATAGT |
| β-actin| Forward TTCTCTCCAAAGTCTCACACAG |
|       | Reverse GGGACAGGAGGCTCATACCTT |

IL6, interleukin 6; CEA, carcinoembryonic antigen; CA125, cancer antigen 125; CYP7A1, cholesterol 7 alpha-hydroxylase; VIM, vimentin; MUC1, mucin 1; CDH2, cadherin 2; β-actin, beta-actin.
suspended in phosphate-buffered saline with 1.5% FBS, 25 mM HEPES pH7.0, and 1 mM EDTA (Sigma-Aldrich) at a concentration of 1×10⁶ cells/mL, stained with fluorescence-conjugated antibodies (anti-CD13-APC, BD Biosciences, San Jose, CA, USA; anti-CD24-eFlour 780, Life Technologies, Carlsbad, CA, USA; anti-CD44-eFlour 450, Life Technologies; anti-CD133-PE, Miltenyi Biotec, Auburn, CA, USA; anti-EpCAM-FITC, Miltenyi Biotec; and 7-AAD, Beckman-Coulter, Brea, CA, USA). Cells stained with isotype-matched antibodies (BD Biosciences) served as negative controls. Flow cytometer analysis was performed on FACSCanto-II Digital Flow Cytometry Analyzer (BD Biosciences) using FlowJo (Tree Star, Ashland, OR, USA) software.

**Statistical analysis**

All experiments were performed in triplicate. Data were analyzed by Prism6 statistical software (GraphPad Software, Inc., San Diego, USA). Measurement data were presented as mean ± standard deviation. Significant differences were determined by repeated measures of ANOVA and/or Tukey’s multiple comparison post-hoc test. A Student’s t-test was used for comparisons between two groups. Differences with $p$ values of <0.05 were considered to be statistically significant.

**Results**

**Cell proliferation**

The effects of FGF19 exposure on H69 cholangiocyte proliferative activity as reflected by Ki67 and WST-1 expression are shown in Figures 1A and B, respectively. After 1 week of exposure, the proliferative activity detected by both parameters was significantly increased in FGF19-exposed cells relative to buffer alone and remained elevated throughout the 6 weeks of exposure to FGF19, before returning towards buffer control levels at 8–12 weeks. FGF4R expression remained relatively stable throughout this period (data not shown).

**Cell invasion**

Cell invasion, as determined by the Transwell migration as-
say, was not consistently altered by exposure to FGF19 (Fig. 2).

**SCSMs**

As shown in Table 2, CD13 and CD90 were highly expressed in H69 cells but the levels of expression did not change with exposure to FGF19. CD24, CD133 and EpCAM expression levels were expressed in less than 10% of cells and expression remained low following FGF19 exposure. Finally, CD44 expression was evident in approximately 25–35% of cells and remained within that range on exposure to all concentrations of FGF19. Thus, overall SCSMs did not appreciably change as a result of FGF19 exposure.

**De-differentiation**

Despite the absence of changes in SCSMs, the state of cell dedifferentiation as reflected by CEA (Fig. 3A) and CA125 (Fig. 3B) expression significantly increased on exposure to FGF19. In both cases, expression of these markers increased at essentially all FGF19 concentrations following 1–2 weeks of exposure, remained elevated throughout the 6-week FGF19 exposure period, and to a lesser extent following withdrawal of FGF19.

Additional evidence of dedifferentiation was obtained

---

**Table 2. Effects of FGF19 exposure on SCSM expression**

|          | CD13  | CD24  | CD44  | CD90  | CD133 | EpCAM |
|----------|-------|-------|-------|-------|-------|-------|
| Baseline | Ctrl  | 99.6±0.5 | 0.6±0.3 | 33.8±3.3 | 100 | 0.1±0.03 | 8.3±0.6 |
|          | 0.5 ng/mL | 97.6±0.8 | 1.0±0.3 | 25.0±1.0 | 99.5±0.5 | 0.3±0.3 | 7.5±1.4 |
|          | 5 ng/mL | 98.6±0.7 | 1.1±0.3 | 25.1±1.5 | 99.9±0.2 | 0.4±0.1 | 6.6±0.6 |
| Week 1   | 50 ng/mL | 97.1±1.1 | 1.1±0.3 | 25.7±1.5 | 100 | 0.5±0.1 | 7.1±1.0 |
| Week 6   | Ctrl  | 99.3±1.2 | 1.5±0.7 | 31±1 | 99.7±0.6 | 0.1±0.03 | 6.7±1.6 |
|          | 0.5 ng/mL | 98.4±1.4 | 0.9±0.6 | 25.3±0.6 | 99.9±0.2 | 0.3±0.2 | 5.7±1.1 |
|          | 5 ng/mL | 98.3±0.6 | 1.2±0.5 | 25.6±2.0 | 99.6±0.6 | 0.1±0.1 | 6.8±0.3 |
|          | 50 ng/mL | 97.9±1.0 | 1.0±0.3 | 26.9±1.7 | 100±0.1 | 0.2±0.2 | 7.7±1.1 |
| Week 8   | Ctrl  | 98.2±1.1 | 1.3±0.6 | 31.9±2.5 | 99.6±0.5 | 0.1±0.1 | 7.6±1.2 |
|          | 0.5 ng/mL | 96.7±2.5 | 1.1±0.4 | 27.8±1.1 | 100 | 0.5±0.3 | 6.4±0.5 |
|          | 5 ng/mL | 97.2±0.8 | 1.0±0.3 | 27.6±0.5 | 100 | 0.5±0.3 | 6.7±2.0 |
|          | 50 ng/mL | 97.6±1.5 | 0.8±0.2 | 28.2±2.0 | 99.6±0.5 | 0.1±0.1 | 7.3±0.6 |
| Week 12  | Ctrl  | 97.2±1.3 | 1.1±0.7 | 31.4±2.2 | 99.9±0.1 | 0.2±0.02 | 5.6±0.5 |
|          | 0.5 ng/mL | 95.3±1.2 | 1.1±0.5 | 29.6±2.9 | 99.8±0.3 | 0.6±0.1 | 7.4±1.4 |
|          | 5 ng/mL | 96.1±1.0 | 1.3±0.6 | 28.1±1.8 | 100 | 0.3±0.02 | 6.6±0.7 |
|          | 50 ng/mL | 98.3±1.2 | 1.1±0.5 | 30.2±0.7 | 99.7±0.6 | 0.4±0.1 | 7.2±1.1 |

CD, cluster of differentiation; EpCAM, epithelial cell adhesion molecule.
Fig. 3. Effects of FGF19 exposure on H69 cholangiocyte differentiation as determined by CEA (A), CA125 (B) and CYP7A1 (C) expression. Data represent mean±standard deviation of at least three experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CEA, carcinoembryonic antigen; CA 125, cancer antigen 125; CYP7A1, cholesterol 7 alpha-hydroxylase; FGF, fibroblast growth factor.
Fig. 4. Effects of FGF19 exposure on H69 cholangiocyte EMT as reflected by vimentin (A), CDH2 (B) and MUC1 (C) expression. Data represent mean±standard deviation of at least three experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. EMT, epithelial mesenchymal transition; FGF, fibroblast growth factor; VIM, vimentin; CDH2, Cadherin 2; MUC1, mucin 1.
Yang J. et al: FGF19 and cholangiocytes

from the loss of differentiated function. CYP7A1 is a CYP450 enzyme involved in the metabolism of cholesterol to bile acids. Within 1 week of FGF19 exposure, CYP7A1 expression was significantly downregulated at all three FGF19 concentrations and remained downregulated throughout the FGF19 exposure period (Fig. 3C). However, recovery of this activity was prompt and not significantly different from buffer controls by week 8.

**EMT**

As occurs with the onset of EMT, expression of the mesenchymal cell marker vimentin significantly increased following 1 week of FGF19 exposure, remained elevated throughout the 6-week exposure period, then rapidly fell towards buffer control levels of expression at weeks 8 and 12 (Fig. 4A). Similarly, CDH2, another marker of the EMT process, significantly increased with FGF19 exposure before returning to buffer control levels at weeks 8 and 12 (Fig. 4B). Conversely, MUC1 expression, an epithelial cell marker, was significantly lower at week 1 and remained low until its expression increased, but for the most part not to buffer control levels at weeks 8 and 12 (Fig. 4C).

**Cytokine expression**

Interleukin (IL)-6 is a proinflammatory cytokine that has been implicated in the pathogenesis of FGF19-induced HCC in rodents. As shown in Figure 5, FGF19 significantly increased IL-6 expression in H69 cells within 1 week of exposure and essentially remained increased (albeit to a lesser extent) until week 12.

**Discussion**

The results of this study indicate that FGF19 significantly influences non-malignant, human cholangiocyte features including cell proliferation, state of differentiation, EMT and IL-6 expression without altering cell invasion or SCSSM expression. However, in essentially all instances, the significant changes identified reverted to baseline or control values within 2–6 weeks of FGF19 withdrawal. These findings suggest that FGF19 exposure is unlikely to be carcinogenic for nonmalignant human cholangiocytes.

As stated earlier, the principal purpose of this study was to determine whether prolonged exposure to FGF19 results in the permanent acquisition of malignant features in non-malignant human cholangiocytes. While the findings of reversibility were somewhat reassuring, it should be noted that 6 weeks of exposure may not have been sufficient to achieve malignant transformation. Also to be noted is the fact that FGF19 induced HCC in mice was documented in vivo, where the contributions of extracellular influences to tumor formation including side populations and angiogenesis may have been relevant. Finally, whether SV-40 transfected cells, such as the H69 cell line employed in this study, have the same threshold for malignant transformation as primary cholangiocytes has yet to be determined.

A secondary objective of the study was to document the effects of FGF19 on cholangiocyte properties that might alter the severity of those liver disorders where FXR agonists are being employed. Here, some interesting findings were observed. Specifically, FGF19 significantly increased H69 proliferation which may be relevant to the replacement of injured cholangiocytes in conditions such as primary biliary cholangitis or primary sclerosing cholangitis. Of note, similar findings were reported by Hannan et al. The increased proliferative activity may also explain the observed dedifferentiation of H69 cells (as manifest by increases in the oncofetoproteins CEA and CA125). That FGF19 exposure-downregulated CYP7A1 expression in H69 cells was a somewhat unexpected finding in that cholesterol metabolism is generally considered a hepatocyte rather than cholangiocyte function. However, Jung et al. reported similar findings and identified the mechanism to involve FGF15/19 binding to FGF4R via the p38 kinase pathway.

EMT is a process observed in fetal tissue development and various carcinomas. It is also observed in tissue repair where epithelial cells transition into fibrogenic cells and serve as modulators of metaloproteins. Thus, the EMT that occurred in H69 cells exposed to FGF19 may represent an important step in the repair of damage associated with chronic liver disease. Conversely, the upregulation of the proinflammatory cytokine IL-6 suggests FGF19 exposure might enhance the severity of those chronic liver disorders.

There are a number of limitations to this study that warrant emphasis. First, as mentioned earlier, 6 weeks of FGF19 exposure may not have been sufficient to effect ma-
lignant transformation. Second, although the concentrations of FGF19 were selected to approximate those reported in the blood of humans being treated with FXR agonists, the intrahepatic concentrations of FGF19 in these individuals is unknown. Third, the duration of FGF19 exposure and recovery period following exposure (a total of 12 weeks) necessitated the use of transformed cholangiocyte cells rather than primary cholangiocytes. Fourth, additional assays such as Ki-67 qIHC and MTT, and those measuring cyclins and proinflammatory cytokines beyond IL-6, were not undertaken.

In conclusion, nonmalignant human cholangiocytes exposed to various concentrations of FGF19 for up to 6 weeks did not undergo malignant transformation. However, the effects observed could theoretically enhance the growth of established CCA. Alternatively, FGF19 exposure may be more relevant to modifying the extent of hepatic injury in patients being treated with FXR agonists.

Acknowledgments

The authors wish to thank Ms R. Vizniak for her prompt and accurate typing of the manuscript.

Funding

None to declare.

Conflict of interest

The authors have no conflict of interests related to this publication.

Author contributions

Study concept and design (GYM), acquisition of data (JY, DS), analysis and interpretation of data (GYM, JY, SK), drafting of the manuscript (GYM), critical revisions of the manuscript for important intellectual content (JY, SK), and administrative, technical, or material support, study supervision (GYM).

Data sharing statement

Data and materials are available upon reasonable request to the corresponding author.

References

[1] Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2(3):REVIEWS3005. doi:10.1186/gb-2001-2-3-reviews3005.
[2] Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16(2):139–149. doi:10.1016/j.cytogfr.2005.01.001.
[3] Siekman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene 2001;271(2):171–182. doi:10.1016/S0378-1119(01)00518-2.
[4] Lin BC, Desnoyers LR. FGF19 and cancer. Adv Exp Med Biol 2012;728:183–194. doi:10.1007/978-1-4614-0887-1_12.
[5] Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2(4):217–225. doi:10.1016/j.cmet.2005.09.001.
[6] Nicholes K, Guillet S, Tomlinson E, Hillan K, Frantz GD, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160(6):2295–2307. doi:10.1016/S0002-9440(10)61777-7.
[7] Desnoyers LR, Pai R, Ferrando RE, Hölzel K, Le T, Ross J, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008;27(1):85–97. doi:10.1038/sj.onc.1210623.
[8] Zhao H, Lu F, Liang G, Huang X, Wu G, Zhang W, et al. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β-catenin signaling cascade via FGFR4 activation. Oncotarget 2016;7(12):13575–13586. doi:10.18632/oncotarget.6185.
[9] van Golen RF, Olthof PB, Lionarons DA, Reiniers MJ, Alles LK, Uz Z, et al. FXR against obestetic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis. Sci Rep 2018;8(1):16529. doi:10.1038/s41598-018-33070-1.
[10] Qureshi HA, Pearl JA, Anderson KA, Green RM. Fibroblast growth factor 19 activates the unfolded protein response and mitogen-activated protein kinase phosphorylation in H-69 cholangiocyte cells. J Liver 2014;3(3):158. doi:10.14722/1267-0889.1000158.
[11] Xu YF, Yang XQ, Lu XF, Guo S, Liu Y, Iqbal M, et al. FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008;27(1):85–97. doi:10.1038/sj.onc.1210623.
[12] Asghari A, Mirzabozorg M, Foroughi F, Tabibi A, Mahmoudi M. FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008;27(1):85–97. doi:10.1038/sj.onc.1210623.
[13] Kaplan MM, Gershwin ME. Primary biliary cirrhosis, N Engl J Med 2005;353(12):1261–1273. doi:10.1056/NEJMra043898.
[14] Mendes FD, Linder KD. Primary sclerosing cholangitis. Clin Liver Dis 2004;8(1):195–211. doi:10.1016/S1089-3261(03)00127-2.
[15] Elaut G, Henkens T, Papeleu P, Snykers S, Vinken M, Vanhaecke T, et al. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab 2006;7(6):629–660. doi:10.2174/13892000678017759.
[16] Lorbeck G, Lewinska M, Romani D. Cytochrome P450s in the synthesis of cholesterol and bile acids—from mouse models to human diseases. FEBS J 2012;279(9):1516–1533. doi:10.1111/j.1742-4658.2011.08432.x.
[17] Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119(6):1420–1428. doi:10.1172/JCI39104.